Ann: Positive Results from Interim Analysis of DurAVR EFS Trial, page-8

ANTERIS RAISES $40 MILLION IN NEW EQUITYAnteris Technologies Ltd (ASX: AVR) (Anteris or the Company) has raised $40 million with the issue oftwo million new ordinary shares (New Shares) at $20 per New Share (Placement).1The funds will be used for preparation for the FDA Pivotal trial of the Company’s DurAVRTM THV fortreating severe aortic stenosis, continued Valve-in-Valve trials and general working capital expenses.The issue of New Shares will be made under the Company’s available placement capacity under Listing Rule 7.1. Evolution Capital acted as manager of the capital raising.The Placement will settle in two tranches of $33.8m on 1 November 2023 and a second tranche of $6.2m anticipated for 15 November 2023.Anteris is developing a new class of biomimetic valve: the world’s only balloon-expandable, single-piece transcatheter aortic valve (TAVR) for the treatment of aortic stenosis. Thus far, it has been implanted in 39 patients with severe aortic stenosis (including three valve-in-valve cases) with outstanding results and superior to current competitor products. The Company expects to publish 30-day results from its Early Feasibility Study in quarter 4 2023 in support of its Pivotal Trial Application with the FDA.